The company's lead drug candidate is pepinemab, a humanized IgG4 monoclonal antibody designed to block SEMA4D. Vaccinex also intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations. The company operates with minimal capital and faces significant clinical and financial execution risks typical of early-stage biotech.
Cyborg Score Rationale
The company reports a net loss of about $20.25 million, and market cap is approximately 2.8M as of April 2026. Vaccinex exhibits 59% estimated likelihood of financial distress. Early clinical-stage assets with no approved products and micro-cap valuation create substantial risk.
Top Insights
SIGNAL-AD Phase 1b/2 trial results announced showed pepinemab treatment inhibited plasma GFAP and p-tau 217 biomarkers in Mild Cognitive Impairment and showed promising trends in slowing cognitive decline in mild dementia patients.
The company's common stock traded on The Nasdaq Capital Market under the symbol VCNX, but has since delisted from Nasdaq in March 2025 and now trades OTC.
The first clinical candidate selected using ActivMAb, CHS‑114 (a fully human monoclonal antibody targeting CCR8), is being developed for cancer immunotherapy by Coherus Biosciences, Inc.
The company has 37 employees and was incorporated in 2001 and is headquartered in Rochester, New York.
Named Competitors
Aducanumab — Anti-amyloid monoclonal antibody for Alzheimer's disease
Donanemab — Anti-amyloid monoclonal antibody for Alzheimer's disease
Keytruda — PD-1 checkpoint inhibitor for cancer immunotherapy
Opdivo — PD-L1 checkpoint inhibitor for cancer immunotherapy
Recent Developments
(April 2026) Released 2025 annual financial results
(Q1 2026) SIGNAL-AD Phase 1b/2 trial results announced showing pepinemab biomarker inhibition and cognitive decline trends in Alzheimer's disease
Open the full interactive Vaccinex, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.